ORILISSA DIN 02481340
Status: Marketed
Holder: ABBVIE CORPORATION
Available to quote
Health Canada record
| Active ingredient(s) | ELAGOLIX (ELAGOLIX SODIUM) 200 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | H01CC03 ELAGOLIX |
|---|
| Original market date | 24-May-2019 |
|---|
| Current status date | 24-May-2019 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
AbbVie Corporation — licence 101988, currently licensed, last inspection rating C (2023-07-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ELAGOLIX (ELAGOLIX SODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02481332 | ORILISSA | ABBVIE CORPORATION | Tablet | ELAGOLIX (ELAGOLIX SODIUM) 150 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 21392 | 2018-10-05 | New Drug Submission (NDS) | |
Request a quote for ORILISSA
How to read a Canadian DIN record